JM’s bullish stance on Krsnaa Diagnostics suggests that they have a positive outlook on the company’s prospects. The brokerage firm likely believes that Krsnaa Diagnostics has been executing its business plan effectively and that it has the potential for further growth in the future.
The report also mentions that JM Financial believes there is significant scope for Krsnaa Diagnostics to re-rate. This suggests that the brokerage expects the company’s valuation to increase in the future, potentially leading to higher stock prices. This could be due to various factors such as improved financial performance, market share gains, or positive industry developments.
It’s important to note that this information is based on the JM Financial report and their analysis of Krsnaa Diagnostics. Investors should conduct their own research and consider various factors before making any investment decisions.
That’s impressive growth for Krsnaa Diagnostics! With 51 CT scan units and 2 MRI machines, they are well-equipped to provide radiology services across India. Additionally, having 168 labs and 3,705 collection centers shows their commitment to making diagnostic services easily accessible to people throughout the country. By expanding their services and establishing various contractual agreements, Krsnaa Diagnostics has positioned itself as a leading provider in both Radiology and Pathology in India.
Krsnaa Diagnostics, the smallcap stock, has recently achieved its 52-week high of Rs 609.15 on June 12, 2023, and its 52-week low of Rs 354 on February 28, 2023. Over the last six months, it has delivered a return of over 35%.
JM Financial has maintained a ‘Buy’ rating on the stock and set a target price of Rs 960. This suggests an upside potential of approximately 98% from the closing price of Rs 485.9 on Thursday. JM Financial mentioned that Krsnaa has successfully operationalized most of its BMC and Orissa collection centers, and this ramp-up is expected to continue over the next few quarters. The company is also actively participating in new large tenders, which will be disclosed in subsequent quarters.
